Candidiasis can be present as a cutaneous, mucosal or deep-seated organ infection, which
is caused by more than 20 types of Candida sp., with C. albicans being the most common …

Background Emerging fungal pathogens pose important threats to global public health. The
World Health Organization has responded to the rising threat of traditionally neglected …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …

Candida auris is an urgent antimicrobial resistance threat due to its global emergence, high
mortality, and persistent transmissions. Nearly half of C. auris clinical and surveillance cases …

Despite improvement of antifungal therapies over the last 30 years, the phenomenon of
antifungal resistance is still of major concern in clinical practice. In the last 10 years the …

Antifungal susceptibility testing of Candida has been standardized and refined and now may
play a useful role in managing Candida infections. Important new developments include …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …

Candida commonly adheres to implanted medical devices, growing as a resilient biofilm
capable of withstanding extraordinarily high antifungal concentrations. As currently available …